Solid forms of 1-(4-(4-((3-(3,6-difluoropyridin-2-yl)-1-((1r,4r)-4-ethoxycyclohexyl)-1h-pyrazol-4-yl)carbamoyl)thiazol-2-yl)-1h-pyrazol-1-yl)ethyl phosphate and salts thereof, and their pharmaceutical compositions and uses

A solid form selected from:

• Form A of potassium salt of 1-(4-(4-((3-(3,6-difluoropyridin-2-yl)-1-((1r,4r)-4-ethoxycyclohexyl)-1H-pyrazol-4-yl)carbamoyl)thiazol-2-yl)-1H-pyrazol-1-yl)ethyl phosphate having an X-ray powder diffraction pattern comprising one or more peaks at approximately 8.64, 16.81 or 17.41 degrees 2θ;
• Form B of potassium salt of 1-(4-(4-((3-(3,6-difluoropyridin-2-yl)-1-((1r,4r)-4-ethoxycyclohexyl)-1H-pyrazol-4-yl)carbamoyl)thiazol-2-yl)-1H-pyrazol-1-yl)ethyl phosphate having an X-ray powder diffraction pattern comprising one or more peaks at approximately 6.41, 10.67 or 14.94 degrees 2θ;
• Form C of potassium salt of 1-(4-(4-((3-(3,6-difluoropyridin-2-yl)-1-((1r,4r)-4-ethoxycyclohexyl)-1H-pyrazol-4-yl)carbamoyl)thiazol-2-yl)-1H-pyrazol-1-yl)ethyl phosphate having an X-ray powder diffraction pattern comprising one or more peaks at approximately 6.67, 8.69 or 16.82 degrees 2θ;
• Form D of potassium salt of 1-(4-(4-((3-(3,6-difluoropyridin-2-yl)-1-((1r,4r)-4-ethoxycyclohexyl)-1H-pyrazol-4-yl)carbamoyl)thiazol-2-yl)-1H-pyrazol-1-yl)ethyl phosphate having an X-ray powder diffraction pattern comprising one or more peaks at approximately 5.20, 15.57 or 17.01 degrees 2θ;
• Form E of potassium salt of 1-(4-(4-((3-(3,6-difluoropyridin-2-yl)-1-((1r,4r)-4-ethoxycyclohexyl)-1H-pyrazol-4-yl)carbamoyl)thiazol-2-yl)-1H-pyrazol-1-yl)ethyl phosphate having an X-ray powder diffraction pattern comprising one or more peaks at approximately 4.28, 6.41 or 8.55 degrees 2θ;
• Form A of magnesium salt of 1-(4-(4-((3-(3,6-difluoropyridin-2-yl)-1-((1r,4r)-4-ethoxycyclohexyl)-1H-pyrazol-4-yl)carbamoyl)thiazol-2-yl)-1H-pyrazol-1-yl)ethyl phosphate having an X-ray powder diffraction pattern comprising one or more peaks at approximately 5.44, 8.16 or 10.90 degrees 2θ;
• Form A of calcium salt of 1-(4-(4-((3-(3,6-difluoropyridin-2-yl)-1-((1r,4r)-4-ethoxycyclohexyl)-1H-pyrazol-4-yl)carbamoyl)thiazol-2-yl)-1H-pyrazol-1-yl)ethyl phosphate having an X-ray powder diffraction pattern comprising one or more peaks at approximately 4.86, 14.56 or 15.73 degrees 2θ;
• Form A of ammonium salt of 1-(4-(4-((3-(3,6-difluoropyridin-2-yl)-1-((1r,4r)-4-ethoxycyclohexyl)-1H-pyrazol-4-yl)carbamoyl)thiazol-2-yl)-1H-pyrazol-1-yl)ethyl phosphate having an X-ray powder diffraction pattern comprising one or more peaks at approximately 8.70, 14.12 or 16.80 degrees 2θ;
• Form A of arginine salt of 1-(4-(4-((3-(3,6-difluoropyridin-2-yl)-1-((1r,4r)-4-ethoxycyclohexyl)-1H-pyrazol-4-yl)carbamoyl)thiazol-2-yl)-1H-pyrazol-1-yl)ethyl phosphate having an X-ray powder diffraction pattern comprising one or more peaks at approximately 4.65, 12.25 or 13.91 degrees 2θ;
• Form B of arginine salt of 1-(4-(4-((3-(3,6-difluoropyridin-2-yl)-1-((1r,4r)-4-ethoxycyclohexyl)-1H-pyrazol-4-yl)carbamoyl)thiazol-2-yl)-1H-pyrazol-1-yl)ethyl phosphate having an X-ray powder diffraction pattern comprising one or more peaks at approximately 8.16, 9.01 or 17.43 degrees 2θ;
• Form C of arginine salt of 1-(4-(4-((3-(3,6-difluoropyridin-2-yl)-1-((1r,4r)-4-ethoxycyclohexyl)-1H-pyrazol-4-yl)carbamoyl)thiazol-2-yl)-1H-pyrazol-1-yl)ethyl phosphate having an X-ray powder diffraction pattern comprising one or more peaks at approximately 4.42, 13.36 or 22.21 degrees 2θ;
• Form A of lysine salt of 1-(4-(4-((3-(3,6-difluoropyridin-2-yl)-1-((1r,4r)-4-ethoxycyclohexyl)-1H-pyrazol-4-yl)carbamoyl)thiazol-2-yl)-1H-pyrazol-1-yl)ethyl phosphate having an X-ray powder diffraction pattern comprising one or more peaks at approximately 4.27, 6.39 or 10.60 degrees 2θ;
• Form A of choline salt of 1-(4-(4-((3-(3,6-difluoropyridin-2-yl)-1-((1r,4r)-4-ethoxycyclohexyl)-1H-pyrazol-4-yl)carbamoyl)thiazol-2-yl)-1H-pyrazol-1-yl)ethyl phosphate having an X-ray powder diffraction pattern comprising one or more peaks at approximately 4.05, 5.22 or 10.07 degrees 2θ;
• Form B of choline salt of 1-(4-(4-((3-(3,6-difluoropyridin-2-yl)-1-((1r,4r)-4-ethoxycyclohexyl)-1H-pyrazol-4-yl)carbamoyl)thiazol-2-yl)-1H-pyrazol-1-yl)ethyl phosphate having an X-ray powder diffraction pattern comprising one or more peaks at approximately 4.07, 5.18 or 12.89 degrees 2θ;
• Form A of tris salt of 1-(4-(4-((3-(3,6-difluoropyridin-2-yl)-1-((1r,4r)-4-ethoxycyclohexyl)-1H-pyrazol-4-yl)carbamoyl)thiazol-2-yl)-1H-pyrazol-1-yl)ethyl phosphate having an X-ray powder diffraction pattern comprising one or more peaks at approximately 4.86, 8.00 or 8.57 degrees 2θ;
• Form B of tris salt of 1-(4-(4-((3-(3,6-difluoropyridin-2-yl)-1-((1r,4r)-4-ethoxycyclohexyl)-1H-pyrazol-4-yl)carbamoyl)thiazol-2-yl)-1H-pyrazol-1-yl)ethyl phosphate having an X-ray powder diffraction pattern comprising one or more peaks at approximately 4.49, 11.16 or 25.55 degrees 2θ;
• Form C of tris salt of 1-(4-(4-((3-(3,6-difluoropyridin-2-yl)-1-((1r,4r)-4-ethoxycyclohexyl)-1H-pyrazol-4-yl)carbamoyl)thiazol-2-yl)-1H-pyrazol-1-yl)ethyl phosphate having an X-ray powder diffraction pattern comprising one or more peaks at approximately 8.56, 16.54 or 17.56 degrees 2θ;
• Form A of 1-(4-(4-((3-(3,6-difluoropyridin-2-yl)-1-((1r,4r)-4-ethoxycyclohexyl)-1H-pyrazol-4-yl)carbamoyl)thiazol-2-yl)-1H-pyrazol-1-yl)ethyl phosphate having an X-ray powder diffraction pattern comprising one or more peaks at approximately 5.51, 20.54 or 25.48 degrees 2θ;
• Form B of 1-(4-(4-((3-(3,6-difluoropyridin-2-yl)-1-((1r,4r)-4-ethoxycyclohexyl)-1H-pyrazol-4-yl)carbamoyl)thiazol-2-yl)-1H-pyrazol-1-yl)ethyl phosphate having an X-ray powder diffraction pattern comprising one or more peaks at approximately 5.53, 11.06 or 12.99 degrees 2θ;
• Form C of 1-(4-(4-((3-(3,6-difluoropyridin-2-yl)-1-((1r,4r)-4-ethoxycyclohexyl)-1H-pyrazol-4-yl)carbamoyl)thiazol-2-yl)-1H-pyrazol-1-yl)ethyl phosphate having an X-ray powder diffraction pattern comprising one or more peaks at approximately 5.35, 12.68 or 17.43 degrees 2θ;
• and
• Form D of 1-(4-(4-((3-(3,6-difluoropyridin-2-yl)-1-((1r,4r)-4-ethoxycyclohexyl)-1H-pyrazol-4-yl)carbamoyl)thiazol-2-yl)-1H-pyrazol-1-yl)ethyl phosphate having an X-ray powder diffraction pattern comprising one or more peaks at approximately 8.73, 16.90 or 17.47 degrees 2θ.